Related Experiment Video
Updated: Jun 7, 2026
03:22
Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
Published on: January 27, 2018
Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes
Bianca Maria Piraccini1, Sergio Vañó-Galván2,3, Ulrike Blume-Peytavi4
1Private Dermatology Practice, Bologna, Italy.
Dermatology and Therapy
|June 5, 2026
Summary
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may be linked to hair loss, particularly with semaglutide and tirzepatide. While causality is unproven, rapid weight loss is a potential mechanism, necessitating clinical awareness and patient monitoring.
Area of Science:
- Endocrinology
- Pharmacology
- Dermatology
Background:
- Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1RAs are widely prescribed for type 2 diabetes and weight management.
- Emerging safety signals in the USA suggest a potential association between GLP-1RA therapies and hair loss.
- Increasing GLP-1RA prescriptions in Europe may lead to a rise in reported hair loss cases.
Purpose of the Study:
- To examine the pharmacological context and market expansion of GLP-1RAs.
- To review the evidence linking GLP-1RAs to hair loss.
- To explore potential pathophysiological mechanisms and propose clinical recommendations.
Main Methods:
- Review of pharmacovigilance database analyses and retrospective cohort studies.
- Examination of pharmacological context and market expansion.
- Exploration of potential pathophysiological mechanisms.
Main Results:
- Most evidence for a GLP-1RA and hair loss link comes from observational studies; causality is not established.
- The association appears strongest for semaglutide and tirzepatide.
- Rapid weight loss induced by these drugs is a potential mechanism for telogen effluvium.
Conclusions:
- Clinicians must be aware of the potential for GLP-1RA-associated hair loss.
- Patients should be informed about this potential risk and monitored accordingly.
- Further research is needed to confirm causality, elucidate mechanisms, and identify risk factors.
Related Concept Videos
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...